Penicilloyl-specific immunoglobulin E (IgE) bound to Fc epsilon receptor I (FcεRI) (Penicilloyl-specific IgE)

Cell-bound IgE antibodies specific for penicilloyl determinants are the primary mediators of Type I hypersensitivity reactions to penicillin (StatPearls: Penicillin Allergy, 2023). These antibodies are formed when the penicilloyl group, the major antigenic determinant of penicillin, conjugates with host proteins to form a hapten-carrier complex that stimulates IgE production. Once produced, these IgE molecules bind with high affinity to the Fc epsilon receptor I (FcεRI) on the surface of mast cells and basophils, sensitizing the individual (PubMed: PMID 11486335). Upon subsequent exposure to penicillin, multivalent penicilloyl-protein conjugates cross-link the cell-bound IgE, triggering the aggregation of FcεRI and the subsequent release of inflammatory mediators such as histamine and leukotrienes. This process can lead to clinical manifestations ranging from localized urticaria to life-threatening systemic anaphylaxis. In clinical settings, these cell-bound antibodies are the specific targets of diagnostic agents like penicilloyl-polylysine, which is used in skin testing to confirm penicillin allergy by inducing a visible wheal-and-flare reaction (FDA: Pre-Pen Prescribing Information). They are also the focus of therapeutic interventions such as rapid drug desensitization, which involves the incremental administration of penicillin to temporarily deplete or desensitize the mast cell response. Furthermore, monoclonal antibodies like omalizumab can indirectly affect this target by binding to circulating IgE, thereby preventing the replenishment of cell-bound IgE and leading to a down-regulation of FcεRI expression on effector cells (PubMed: PMID 16466515). Understanding the interaction between penicilloyl determinants and cell-bound IgE is essential for the safe administration of beta-lactam antibiotics in sensitized patients.

Other names

Penicillin-specific IgEAnti-penicilloyl IgEMajor determinant-specific IgECell-bound penicilloyl-IgEIgE anti-benzylpenicilloyl

Diagnostic agents like penicilloyl-polylysine cross-link cell-bound IgE to trigger receptor aggregation and mediator release for allergy confirmation, while therapeutic agents like omalizumab reduce the density of these complexes by sequestering free IgE and down-regulating FcεRI expression (PubMed: PMID 16466515).